Fujifilm to Invest $200 Million to Expand Cell Therapy Development, Manufacturing Capabilities
By Ronnie Harui
Fujifilm plans to invest $200 million in two subsidiaries in the U.S. to expand its global cell therapy contract development and manufacturing capabilities, the Japanese conglomerate said Tuesday.
The investment is earmarked for the new headquarters of Fujifilm Cellular Dynamics in Wisconsin and the California site of Fujifilm Diosynth Biotechnologies, Fujifilm said in a statement. The investment will enable Fujifilm to support the expanding cell therapy market, which is expected to grow by more than 30% a year from an estimated $3.3 billion in fiscal 2022, it added.
Cell therapies are a promising treatment with the ability to augment, repair and replace human biology, including organs, tissues and cells, Fujifilm said.
Write to Ronnie Harui at ronnie.harui@wsj.com
(END) Dow Jones Newswires
December 04, 2023 23:14 ET (04:14 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
After Earnings, Is Alphabet Stock a Buy, a Sell, or Fairly Valued?
-
When Will the Fed Start Cutting Interest Rates?
-
What’s the Difference Between the CPI and PCE Indexes?
-
Powell Unfazed By Sticky Inflation, but Rate Cuts Are Far Off
-
After Earnings, Is Microsoft Stock a Buy, a Sell, or Fairly Valued?
-
Best- and Worst-Performing Stocks of April 2024
-
Magnificent 7 Stocks Earnings Updates: AI Remains the Focus
-
Small-Cap and Value Stocks Are Undervalued
-
4 Utility Stocks to Play the AI Data Center Boom
-
Albemarle Earnings: We Expect Improved Results In the Rest of Year Following Cyclically Low Profits
-
Novo Nordisk Earnings: Raised Fair Value Estimate Still a Contrast to Market Overenthusiasm
-
After Earnings, Is Verizon Stock a Buy, a Sell, or Fairly Valued?
-
Look Inside Berkshire Hathaway’s Portfolio Before Its Annual Meeting
-
How to Invest Like Warren Buffett
-
Cognizant Earnings: Improved Profitability Buttresses Results as Customer Spending Remains Muted
-
10 Top-Performing Dividend Stocks of the Month